Savara Inc (SVRA) — SEC Filings
Savara Inc (SVRA) — 46 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 16 8-K, 10 SC 13G/A, 7 SC 13G.
Overview
Savara Inc (SVRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Savara Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $86.6 million, up from $66.8 million in the same period of 2024, representing a 29.6% increase. This was primarily driven by a substantial rise in total operating expenses, which climbed to
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 42 neutral. The dominant filing sentiment for Savara Inc is neutral.
Filing Type Overview
Savara Inc (SVRA) has filed 6 10-Q, 16 8-K, 2 DEF 14A, 1 10-K/A, 2 10-K, 7 SC 13G, 10 SC 13G/A, 1 SC 13D/A, 1 8-K/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of SVRA's 28 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$86.6M |
| EPS | -$0.40 |
| Debt-to-Equity | 0.49 |
| Cash Position | $16.3M |
| Operating Margin | N/A |
| Total Assets | $140.9M |
| Total Debt | $29.8M |
Key Executives
- Dr. Robert L. Neville
- Dr. Claire Davies
- ALI BEHBAHANI
- ANTHONY A. FLORENCE, JR.
- CARMEN CHANG
- EDWARD T. MATHERS
- FOREST BASKETT
Industry Context
Savara operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on rare diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success is often dependent on a few key drug candidates, making pipeline diversification a common strategy, which Savara currently lacks.
Top Tags
pharmaceuticals (6) · corporate-governance (5) · financials (5) · 10-Q (4) · amendment (4) · institutional-ownership (4) · material-agreement (3) · Savara Inc. (3) · Clinical Stage (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $86.6M | Increased from $66.8M in 2024 for the nine months ended September 30, 2025, a 29.6% increase. |
| Total Operating Expenses | $90.1M | Increased from $72.0M in 2024 for the nine months ended September 30, 2025, a 25.1% increase. |
| Research and Development Expenses | $60.5M | Increased from $54.7M in 2024 for the nine months ended September 30, 2025. |
| General and Administrative Expenses | $29.5M | Increased from $17.2M in 2024 for the nine months ended September 30, 2025. |
| Net Proceeds from Public Offering | $140.0M | Received on October 31, 2025, providing liquidity for at least the next twelve months. |
| Cash and Cash Equivalents | $16.3M | As of September 30, 2025, a slight increase from $15.1M at December 31, 2024. |
| Short-term Investments | $108.1M | As of September 30, 2025, a significant decrease from $181.2M at December 31, 2024. |
| Accumulated Deficit | $575.9M | As of September 30, 2025, reflecting cumulative losses since inception. |
| Cash Used in Operating Activities | $76.0M | For the nine months ended September 30, 2025, indicating ongoing cash burn. |
| Common Stock Shares Outstanding | 203,467,845 | As of November 12, 2025, indicating potential dilution. |
| SEC File Number | 001-32157 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 84-1318182 | Company's tax identification number |
| Common Shares Outstanding | 172,836,922 | as of August 13, 2025, up from 172,423,223 at December 31, 2024 |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter covered by the report. |
| Filing Date | 2025-05-13 | The date the 10-Q report was officially submitted to the SEC. |
Forward-Looking Statements
- {"claim":"Savara Inc. stock may experience increased trading volume due to heightened institutional interest.","entity":"Savara Inc.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Savara Inc (SVRA)?
Savara Inc has 46 recent SEC filings from Jan 2024 to Nov 2025, including 16 8-K, 10 SC 13G/A, 7 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SVRA filings?
Across 46 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 42 neutral. The dominant sentiment is neutral.
Where can I find Savara Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Savara Inc (SVRA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Savara Inc?
Key financial highlights from Savara Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SVRA?
The investment thesis for SVRA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Savara Inc?
Key executives identified across Savara Inc's filings include Dr. Robert L. Neville, Dr. Claire Davies, ALI BEHBAHANI, ANTHONY A. FLORENCE, JR., CARMEN CHANG and 2 others.
What are the main risk factors for Savara Inc stock?
Of SVRA's 28 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Savara Inc?
Recent forward-looking statements from Savara Inc include guidance on {"claim":"Savara Inc. stock may experience increased trading volume due to heightened institutional interest.","entity":.